| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1037508442 |
| P356 | DOI | 10.1007/S00125-013-2991-0 |
| P8608 | Fatcat ID | release_rerxv7tsxnf3jdt232wfgkeoyi |
| P3181 | OpenCitations bibliographic resource ID | 88169 |
| P932 | PMC publication ID | 3737434 |
| P698 | PubMed publication ID | 23835523 |
| P5875 | ResearchGate publication ID | 247771646 |
| P50 | author | Ewan Pearson | Q56240082 |
| Graham Rena | Q72997557 | ||
| P2093 | author name string | Kei Sakamoto | |
| P2860 | cites work | Metformin Increases AMP-Activated Protein Kinase Activity in Skeletal Muscle of Subjects With Type 2 Diabetes | Q22241283 |
| The blooming of the French lilac | Q22241897 | ||
| Role of AMP-activated protein kinase in mechanism of metformin action | Q22241898 | ||
| Metformin | Q22250907 | ||
| Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP | Q22251081 | ||
| Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus | Q22253064 | ||
| Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus | Q24235718 | ||
| Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus | Q24244739 | ||
| The selectivity of protein kinase inhibitors: a further update | Q24654622 | ||
| Cellular and molecular mechanisms of metformin: an overview | Q27013561 | ||
| Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice | Q28510615 | ||
| The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin | Q28590162 | ||
| Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 | ||
| Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain | Q29615210 | ||
| AMPK: a nutrient and energy sensor that maintains energy homeostasis | Q29615410 | ||
| Metformin and reduced risk of cancer in diabetic patients | Q29616275 | ||
| AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism | Q29617261 | ||
| The specificities of small molecule inhibitors of the TGFß and BMP pathways | Q33956096 | ||
| Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state | Q33968008 | ||
| Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. | Q34086275 | ||
| CREB and the CRTC co-activators: sensors for hormonal and metabolic signals | Q34166530 | ||
| Effects of guanidine derivatives on mitochondrial function. I. Phenethylbiguanide inhibition of respiration in mitochondria from guinea pig and rat tissues | Q34279634 | ||
| Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics | Q34292544 | ||
| Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. | Q34506457 | ||
| LKB1-dependent signaling pathways | Q34535140 | ||
| Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes | Q34539510 | ||
| Calcium-like Action of Phenethylbiguanide and Related Compounds: Inhibition of Pyruvate Kinase | Q34718181 | ||
| Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes | Q34862358 | ||
| Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action | Q35762110 | ||
| The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review | Q35800117 | ||
| Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis | Q35842470 | ||
| Hypoglycemia, hyperglucagonemia, and fetoplacental defects in glucagon receptor knockout mice: a role for glucagon action in pregnancy maintenance. | Q35849360 | ||
| Cellular responses to the metal-binding properties of metformin. | Q35976604 | ||
| A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts. | Q36013520 | ||
| Defining the contribution of AMP-activated protein kinase (AMPK) and protein kinase C (PKC) in regulation of glucose uptake by metformin in skeletal muscle cells | Q36016832 | ||
| AMP-activated protein kinase as a drug target. | Q36551887 | ||
| Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications | Q36808739 | ||
| Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study | Q37193773 | ||
| New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes | Q37319178 | ||
| Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control | Q37621774 | ||
| An energetic tale of AMPK-independent effects of metformin. | Q37767575 | ||
| Hormonal regulation of hepatic glucose production in health and disease | Q37896899 | ||
| The alpha-cell as target for type 2 diabetes therapy. | Q37977335 | ||
| Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. | Q38298758 | ||
| Effects of guanidine derivatives on mitochondrial function. 3. The mechanism of phenethylbiguanide accumulation and its relationship to in vitro respiratory inhibition. | Q38362681 | ||
| Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation | Q39697365 | ||
| Lactic acidosis in biguanide-treated diabetics: a review of 330 cases | Q39718414 | ||
| Guanidine Derivatives in Medicine | Q39927463 | ||
| Tailoring cAMP-signalling responses through isoform multiplicity | Q41516369 | ||
| Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells | Q41604474 | ||
| Evidence that the flux control coefficient of the respiratory chain is high during gluconeogenesis from lactate in hepatocytes from starved rats. Implications for the hormonal control of gluconeogenesis and action of hypoglycaemic agents | Q41849151 | ||
| Inhibitory effects of metformin on insulin and glucagon action in rat hepatocytes involve post-receptor alterations | Q42517708 | ||
| Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells | Q44468960 | ||
| Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? | Q44816749 | ||
| Regeneration of the heart in diabetes by selective copper chelation | Q45032429 | ||
| Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study | Q45389552 | ||
| A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study | Q46145344 | ||
| Thienopyridone drugs are selective activators of AMP-activated protein kinase beta1-containing complexes. | Q46236023 | ||
| Demonstration of a hyperglycemia-driven pathogenic abnormality of copper homeostasis in diabetes and its reversibility by selective chelation: quantitative comparisons between the biology of copper and eight other nutritionally essential elements in | Q46458763 | ||
| Metformin decreases intracellular production of reactive oxygen species in aortic endothelial cells | Q46523954 | ||
| Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase | Q46917092 | ||
| Marked Hyperlipidemia and Pancreatitis Associated with Oral Contraceptive Therapy | Q47981050 | ||
| The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. | Q50510276 | ||
| Effects of metformin on glucose and glucagon regulated gluconeogenesis in cultured normal and diabetic hepatocytes. | Q51594182 | ||
| über Synthetisch Dargestellte Körper mit Insulinartiger Wirkung Auf den Normalen und Diabetischen Organismus | Q56444436 | ||
| Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | Q57412648 | ||
| Metformin treatment of lean and obese Zucker rats modulates the ability of glucagon and insulin to regulate hepatocyte adenylate cyclase activity | Q57910695 | ||
| Specific Inhibition of Gluconeogenesis by Biguanides | Q58982690 | ||
| Biguanides | Q67291826 | ||
| On the mechanism of action of hypoglycemia-producing biguanides. A reevaluation and a molecular theory | Q67851216 | ||
| Mode of action of hypoglycemic agents. V. Studies with phenethylbiguanide in isolated perfused rat liver | Q69637534 | ||
| Effect of metformin on glucose metabolism in mouse soleus muscle | Q69640883 | ||
| The interaction of fructose 2,6-bisphosphate and AMP with rat hepatic fructose 1,6-bisphosphatase | Q71245975 | ||
| Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production | Q72020678 | ||
| Accumulation of metformin by tissues of the normal and diabetic mouse | Q72381698 | ||
| Inhibition of electron and energy transfer in mitochondria. II. The site and the mechanism of guanidine action | Q76463507 | ||
| The relation of synthalin to carbohydrate metabolism | Q80326312 | ||
| ??? | Q64895651 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 2.0 Generic | Q44128984 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | metformin | Q19484 |
| amidines | Q423088 | ||
| P304 | page(s) | 1898-1906 | |
| P577 | publication date | 2013-07-09 | |
| P1433 | published in | Diabetologia | Q5270140 |
| P1476 | title | Molecular mechanism of action of metformin: old or new insights? | |
| P478 | volume | 56 |
| Q90192600 | A Cohort Study of Exposure to Antihyperglycemic Therapy and Survival in Patients with Lung Cancer |
| Q37005064 | A Common Variant at the 14q32 Endometrial Cancer Risk Locus Activates AKT1 through YY1 Binding |
| Q64232987 | A Novel Dipeptide NGF Mimetic GK-2 Selectively Activating the PI3K/AKT Signaling Pathway Promotes the Survival of Pancreatic β-Cells in a Rat Model of Diabetes |
| Q51281697 | A novel polymorphism in protein kinase AMP-activated catalytic subunit alpha 2 (PRKAA2) is associated with type 2 diabetes in the Han Chinese population. |
| Q47240106 | A reappraisal on metformin |
| Q94526301 | A review of cancer immunotherapy: from the past, to the present, to the future |
| Q54365047 | A small-molecule benzimidazole derivative that potently activates AMPK to increase glucose transport in skeletal muscle: comparison with effects of contraction and other AMPK activators. |
| Q35859585 | AMP-activated Protein Kinase Suppresses Biosynthesis of Glucosylceramide by Reducing Intracellular Sugar Nucleotides |
| Q92601237 | AMPK Alpha-1 Intrinsically Regulates the Function and Differentiation of Tumor Myeloid-Derived Suppressor Cells |
| Q33824564 | AMPK activation: a therapeutic target for type 2 diabetes? |
| Q57170002 | AMPK: Potential Therapeutic Target for Ischemic Stroke |
| Q43809926 | Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial |
| Q38734414 | Activation of the metabolic sensor AMP-activated protein kinase inhibits aquaporin-2 function in kidney principal cells |
| Q37692552 | Adipokines and insulin action: A sensitive issue |
| Q90221587 | Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease |
| Q90478040 | Advanced and multifaceted stability profiling of the first-line antidiabetic drugs metformin, gliclazide and glipizide under various controlled stress conditions |
| Q40296763 | Aging metabolism: intervention strategies |
| Q34003050 | An update on the pharmacogenomics of metformin: progress, problems and potential |
| Q37187900 | Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status |
| Q57281750 | Anti-metastatic effect of metformin via repression of interleukin 6-induced epithelial-mesenchymal transition in human colon cancer cells |
| Q40251170 | Association between the synonymous variant organic cation transporter 3 (OCT3)-1233G>A and the glycemic response following metformin therapy in patients with type 2 diabetes |
| Q35675566 | Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study. |
| Q91597975 | Back to basics with active lifestyles: exercise is more effective than metformin to reduce cardiovascular risk in older adults with type 2 diabetes |
| Q28541332 | Berberine promotes glucose consumption independently of AMP-activated protein kinase activation |
| Q64941870 | Bidirectional regulation of adenosine 5'-monophosphate-activated protein kinase activity by berberine and metformin in response to changes in ambient glucose concentration. |
| Q65002446 | Capsaicin Analogues Derived from n-3 Polyunsaturated Fatty Acids (PUFAs) Reduce Inflammatory Activity of Macrophages and Stimulate Insulin Secretion by β-Cells In Vitro. |
| Q42372108 | Cardioprotective effect of metformin against doxorubicin cardiotoxicity in rats |
| Q34383575 | Cardiovascular impact of drugs used in the treatment of diabetes |
| Q36520595 | Case-control study of oral glucose-lowering drugs in combination with long-acting insulin and the risks of incident myocardial infarction and incident stroke |
| Q38147723 | Clinical relevance of target identity and biology: implications for drug discovery and development |
| Q38945649 | Combatting type 2 diabetes by turning up the heat |
| Q33605925 | Combination of metformin and curcumin targets breast cancer in mice by angiogenesis inhibition, immune system modulation and induction of p53 independent apoptosis |
| Q35800392 | Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth. |
| Q26740253 | Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile? |
| Q47817158 | Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide--a randomised controlled trial |
| Q30373454 | Concise Review: Macrophages: Versatile Gatekeepers During Pancreatic β-Cell Development, Injury, and Regeneration. |
| Q26778957 | Development, Maintenance, and Reversal of Multiple Drug Resistance: At the Crossroads of TFPI1, ABC Transporters, and HIF1 |
| Q36427543 | Disease, Models, Variants and Altered Pathways-Journeying RGD Through the Magnifying Glass |
| Q47144635 | Dual Therapy Appears Superior to Monotherapy for Low-Income Individuals With Newly Diagnosed Type 2 Diabetes. |
| Q35535310 | Effect comparison of metformin with insulin treatment for gestational diabetes: a meta-analysis based on RCTs |
| Q38948037 | Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control |
| Q48089757 | Effect of metformin on germ cell-specific apoptosis, oxidative stress and epididymal sperm quality after testicular torsion/detorsion in rats. |
| Q35944675 | Effects of caloric restriction and low glycemic index diets associated with metformin on glucose metabolism and cortisol response in overweight/obese subjects: a case series study. |
| Q27003253 | Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain |
| Q45718198 | Endogenous glucose production increases in response to metformin treatment in the glycogen-depleted state in humans: a randomised trial. |
| Q37629041 | Enhanced activation of cellular AMPK by dual-small molecule treatment: AICAR and A769662. |
| Q40989059 | Epithelial-Mesenchymal Transition Phenotype, Metformin, and Survival for Colorectal Cancer Patients with Diabetes Mellitus II. |
| Q38607553 | Evidence-based prioritisation and enrichment of genes interacting with metformin in type 2 diabetes. |
| Q48042047 | Functional interplay between LXR and AMPKα inhibits atherosclerosis in apoE deficient mice - A new anti-atherogenic strategy. |
| Q53411897 | Genetic Variants in CPA6 and PRPF31 are Associated with Variation in Response to Metformin in Individuals with Type 2 Diabetes. |
| Q89462733 | Ginsenoside Rg5 attenuates hepatic glucagon response via suppression of succinate-associated HIF-1α induction in HFD-fed mice |
| Q36253720 | Global Phosphoproteomic Analysis of Human Skeletal Muscle Reveals a Network of Exercise-Regulated Kinases and AMPK Substrates. |
| Q91991851 | Gut microbiome differences between metformin- and liraglutide-treated T2DM subjects |
| Q35725065 | Gut microorganisms as promising targets for the management of type 2 diabetes |
| Q44655644 | Head and neck cancers, the neglected malignancies: present and future treatment strategies |
| Q57180762 | Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology |
| Q36016417 | Identification of matrine as a promising novel drug for hepatic steatosis and glucose intolerance with HSP72 as an upstream target |
| Q34989872 | Increased methylglyoxal formation with upregulation of renin angiotensin system in fructose fed Sprague Dawley rats |
| Q35935123 | Interventions to Slow Aging in Humans: Are We Ready? |
| Q28829020 | Investigation of salicylate hepatic responses in comparison with chemical analogues of the drug |
| Q35685308 | Isothiocyanate-rich Moringa oleifera extract reduces weight gain, insulin resistance, and hepatic gluconeogenesis in mice |
| Q47252413 | Lean Body Weight and Metformin Are Insufficient to Prevent Endometrial Hyperplasia in Mice Harboring Inactivating Mutations in PTEN. |
| Q53706040 | Meta- and cross-species analyses of insulin resistance based on gene expression datasets in human white adipose tissues. |
| Q39318607 | Metabolic Alterations at the Crossroad of Aging and Oncogenesis |
| Q51533022 | Metformin Attenuates Aβ Pathology Mediated Through Levamisole Sensitive Nicotinic Acetylcholine Receptors in a C. elegans Model of Alzheimer's Disease. |
| Q37314264 | Metformin Increases Cortisol Regeneration by 11βHSD1 in Obese Men With and Without Type 2 Diabetes Mellitus |
| Q91854786 | Metformin activates KDM2A to reduce rRNA transcription and cell proliferation by dual regulation of AMPK activity and intracellular succinate level |
| Q58723952 | Metformin added to bosentan therapy in patients with pulmonary arterial hypertension associated with congenital heart defects: a pilot study |
| Q35853068 | Metformin alleviates hepatosteatosis by restoring SIRT1-mediated autophagy induction via an AMP-activated protein kinase-independent pathway |
| Q35858703 | Metformin and Resveratrol Inhibited High Glucose-Induced Metabolic Memory of Endothelial Senescence through SIRT1/p300/p53/p21 Pathway |
| Q28082736 | Metformin and metabolic diseases: a focus on hepatic aspects |
| Q61801352 | Metformin and the Risk of Dementia in Type 2 Diabetes Patients |
| Q34151605 | Metformin attenuates experimental autoimmune arthritis through reciprocal regulation of Th17/Treg balance and osteoclastogenesis |
| Q41038714 | Metformin causes a futile intestinal-hepatic cycle which increases energy expenditure and slows down development of a type 2 diabetes-like state |
| Q42256796 | Metformin directly binds the alarmin HMGB1 and inhibits its proinflammatory activity. |
| Q53692797 | Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7-9 years of age. |
| Q28539104 | Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells |
| Q49180657 | Metformin induces distinct bioenergetic and metabolic profiles in sensitive versus resistant high grade serous ovarian cancer and normal fallopian tube secretory epithelial cells |
| Q64105328 | Metformin induces the AP-1 transcription factor network in normal dermal fibroblasts |
| Q34505650 | Metformin is not just an antihyperglycaemic drug but also has protective effects on the vascular endothelium |
| Q38834937 | Metformin prevents DMH-induced colorectal cancer in diabetic rats by reversing the warburg effect |
| Q47297378 | Metformin prevents ischaemic ventricular fibrillation in metabolically normal pigs |
| Q55342484 | Metformin reduces insulin resistance and the tendency toward hyperglycaemia and dyslipidaemia in dogs with hyperadrenocorticism. |
| Q59882737 | Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase |
| Q98386080 | Metformin reduces saturated fatty acid-induced lipid accumulation and inflammatory response by restoration of autophagic flux in endothelial cells |
| Q42362632 | Metformin selectively targets redox control of complex I energy transduction |
| Q37364089 | Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials |
| Q36103093 | Metformin use and its effect on survival in diabetic patients with advanced non-small cell lung cancer |
| Q35046673 | Metformin use and lung cancer risk in patients with diabetes. |
| Q40930334 | Metformin use improves the survival of diabetic combined small-cell lung cancer patients |
| Q92383575 | Metformin use is associated with a lower risk of uterine leiomyoma in female type 2 diabetes patients |
| Q97643486 | Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss |
| Q26999344 | Metformin: An Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the Endothelium |
| Q43576506 | Metformin: an old drug with new potential |
| Q41866726 | Mulberry leaf alleviates streptozotocin-induced diabetic rats by attenuating NEFA signaling and modulating intestinal microflora |
| Q40949691 | NHX-5, an Endosomal Na+/H+ Exchanger, Is Associated with Metformin Action. |
| Q92538820 | NK Cell Metabolism and TGFβ - Implications for Immunotherapy |
| Q47551363 | Negative Effects of Chronic Rapamycin Treatment on Behavior in a Mouse Model of Fragile X Syndrome. |
| Q26786307 | Neuropharmacological Actions of Metformin in Stroke |
| Q41669655 | New Evidence for the Mechanism of Action of a Type-2 Diabetes Drug Using a Magnetic Bead-Based Automated Biosensing Platform |
| Q33838229 | Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. |
| Q38374396 | Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease |
| Q37673171 | Nutrients in Energy and One-Carbon Metabolism: Learning from Metformin Users. |
| Q54946332 | Obesity as disruptor of the female fertility. |
| Q53723216 | Oxamate Enhances the Anti-Inflammatory and Insulin-Sensitizing Effects of Metformin in Diabetic Mice. |
| Q38747416 | Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool? |
| Q38816602 | Pharmacogenetics: Implications for Modern Type 2 Diabetes Therapy |
| Q49850150 | Pharmacokinetics of metformin in patients with gastrointestinal intolerance |
| Q92031590 | Physiologically-Based Pharmacokinetic Modeling Analysis for Quantitative Prediction of Renal Transporter-Mediated Interactions Between Metformin and Cimetidine |
| Q41428466 | Predicting Clostridium difficile infection in diabetic patients and the effect of metformin therapy: a retrospective, case-control study |
| Q34776628 | Prenatal metformin exposure in a maternal high fat diet mouse model alters the transcriptome and modifies the metabolic responses of the offspring. |
| Q93038010 | Prenatal metformin exposure or organic cation transporter 3 knock-out curbs social interaction preference in male mice |
| Q40847551 | Prognosis of small cell lung cancer patients with diabetes treated with metformin |
| Q39814876 | Re-sensitization of radiation resistant colorectal cancer cells to radiation through inhibition of AMPK pathway |
| Q90312494 | Recent Advances in Anti-Aging Medicine |
| Q33616159 | Recent progress in metabolic signaling pathways regulating aging and life span |
| Q36800163 | Recessive mutations in the cancer gene Ataxia Telangiectasia Mutated (ATM), at a locus previously associated with metformin response, cause dysglycaemia and insulin resistance |
| Q42775670 | Reduced mitochondrial activity in colonocytes facilitates AMPKα2-dependent inflammation |
| Q89371436 | Regulation of hepatic glucose production and AMPK by AICAR but not by metformin depends on drug uptake through the equilibrative nucleoside transporter 1 (ENT1) |
| Q58739088 | Repurposing of Drugs Targeting YAP-TEAD Functions |
| Q38225855 | Revisiting "Vegetables" to combat modern epidemic of imbalanced glucose homeostasis |
| Q38800502 | Rh2E2, a novel metabolic suppressor, specifically inhibits energy-based metabolism of tumor cells. |
| Q54382901 | Rictor/mTORC2 protects against cisplatin-induced tubular cell death and acute kidney injury. |
| Q41021948 | Salicylic acid: old and new implications for the treatment of type 2 diabetes? |
| Q51439096 | Sequential cleavage of insulin receptor by calpain 2 and γ-secretase impairs insulin signalling. |
| Q92128838 | Small molecule IVQ, as a prodrug of gluconeogenesis inhibitor QVO, efficiently ameliorates glucose homeostasis in type 2 diabetic mice |
| Q26865663 | Something old, something new and something very old: drugs for treating type 2 diabetes |
| Q85487123 | Suppression of experimental arthritis through AMP-activated protein kinase activation and autophagy modulation |
| Q35153493 | Survival of patients with stage IV lung cancer with diabetes treated with metformin |
| Q97539453 | T Cell Metabolism in Cancer Immunotherapy |
| Q52661722 | Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy. |
| Q38586248 | The Bidirectional Relationship between Metabolism and Immune Responses |
| Q40842440 | The Effect of Metformin Use on Left Ventricular Ejection Fraction and Mortality Post-Myocardial Infarction |
| Q34086454 | The LKB1-salt-inducible kinase pathway functions as a key gluconeogenic suppressor in the liver |
| Q89862360 | The Surprising Effect of Phenformin on Cutaneous Darkening and Characterization of Its Underlying Mechanism by a Forward Chemical Genetics Approach |
| Q57086835 | The copper binding properties of metformin – QCM-D, XPS and nanobead agglomeration |
| Q38996030 | The emerging role of metformin in gestational diabetes mellitus |
| Q33804241 | The role of genetic factors and kidney and liver function in glycemic control in type 2 diabetes patients on long-term metformin and sulphonylurea cotreatment |
| Q35880380 | Therapeutic Challenges in Diabetes Prevention: We Have Not Found the "Exercise Pill" |
| Q35761723 | Therapeutic Concentrations of Metformin: A Systematic Review |
| Q38823805 | Therapeutic Potential of Antidiabetic Medications in the Treatment of Cognitive Dysfunction and Dementia |
| Q33787067 | To Use or Not to Use Metformin in Cerebral Ischemia: A Review of the Application of Metformin in Stroke Rodents |
| Q39630588 | Traumatic brain injury decreases AMP-activated protein kinase activity and pharmacological enhancement of its activity improves cognitive outcome. |
| Q44510337 | Two-cell embryos are more sensitive than blastocysts to AMPK-dependent suppression of anabolism and stemness by commonly used fertility drugs, a diet supplement, and stress |
| Q30240030 | Understanding and overcoming metformin gastrointestinal intolerance. |
| Q54976706 | Why AMPK agonists not known to be stressors may surprisingly contribute to miscarriage or hinder IVF/ART. |
Search more.